Healthcare
ClearPoint Neuro Inc(CLPT)
Live Price
Offline$17.77
+5.71% today
1Y Change
+54.16%
Window
Jun 26, 2025 โ Jun 23, 2026
- Market Cap
- $330.00M
- Revenue Growth
- +17.8%
- EPS Growth
- -28.6%
- Dividend Yield
- 0.0%
Coverage: 248 bars ยท Jun 26, 2025 โ Jun 23, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
ClearPoint Neuro Inc (CLPT) is a Healthcare stock with a market cap of $330.00M and listed on NASDAQ. The stock last traded around $17.77 and up 54.2% across the available one-year price window (Jun 26, 2025 โ Jun 23, 2026). Baseline metrics include revenue growth of +17.8%, EPS growth of -28.6%, a dividend yield of 0.0%. What stands out right now is revenue +17.8%, EPS -28.6%, free cash flow -165.0% with operating margin -65.4% and ROIC -27.6%. Valuation already assumes a fairly strong business story at price/sales 9.0. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines CLPT price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+17.8% vs +7.6% peer median
Operating Margin
Below sector median
-65.4% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 12, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at +17.8% and EPS is at -28.6%, with operating margin around -65.4%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -14.1% over the next 5 trading days and finished higher after 0 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 12, 2026 | โ | -3.6% | -11.6% | +8.8% |
2026 Mar 17, 2026 | -22.7% | -13.9% | -15.6% | -6.3% |
2025 Nov 6, 2025 | -5.0% | -13.3% | -15.0% | -25.7% |
Benchmark Edge
CLPT vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
CLPT
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
CLPT Max Drawdown
-70.74%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for CLPT and SPY.
Company Overview
ClearPoint Neuro Inc
NASDAQ
ClearPoint Neuro Inc. is a global device, cell, and gene therapy-enabling company specializing in precise navigation and delivery systems to the brain and spine. It develops and commercializes platforms like the ClearPoint system for minimally invasive neurosurgical procedures under real-time MRI guidance, supporting deep brain stimulation electrode insertions, biopsies, laser catheter placements, and pharmaceutical infusions. The company offers established clinical products alongside pre-clinical development services for controlled drug and device delivery, including the SmartFlow cannula for gene therapy and the ClearPoint Prism Neuro Laser Therapy System. ClearPoint Neuro also provides the IRRAflow system for active intracranial fluid management following its acquisition of IRRAS. Engaged with over 90 neurosurgery centers and more than 60 biologics and drug delivery partners worldwide across North America, Europe, Asia, and South America, it supports healthcare professionals, researchers, and biopharma in translational research, clinical trials, and patient treatments for complex neurological disorders. Founded in 1998 and headquartered in Solana Beach, California, ClearPoint Neuro maintains a dedicated focus on the neuro space through its Global Training and Innovation Center.
- Leadership
- Mr. Joseph Michael Burnett
- Employees
- 172
- Street Address
- 120 S. Sierra Avenue, Suite 100
- Mailing
- Solana Beach, CA, 92075
- Region
- Solana Beach, CA, United States
- Last Updated
- May 8, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 9.0
- Price/Book
- 11.2
Growth
- Revenue
- +17.8%
- EPS
- -28.6%
- Free Cash Flow
- -165.0%
Profitability
- Gross Margin
- 61.4%
- Operating Margin
- -65.4%
- Net Margin
- -69.1%
- ROE
- -122.2%
- ROIC
- -27.6%
Balance Sheet
- Debt/Equity
- 2.08
- Current Ratio
- 5.91
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.